Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
RC28-E / Rongchang Pharma
NCT05727397: Efficacy and Safety of RC28-E Versus Aflibercept	Recruiting	3	432	RoW	RC28-E, Aflibercept, Eylea	RemeGen Co., Ltd.	Wet Age-related Macular Degeneration	11/25	12/25
NCT05885503: Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema	Recruiting	3	316	RoW	RC-28E, Aflibercept	RemeGen Co., Ltd.	Diabetic Macular Edema	06/26	06/26
NCT04782115: Evaluation of RC28-E Injection in Diabetic Macular Edema	Completed	2	156	RoW	intravitreal injection of RC28-E, Conbercept	RemeGen Co., Ltd.	Diabetic Macular Edema	07/23	07/23
NCT04782128: Evaluation of RC28-E Injection in Diabetic Retinopathy	Active, not recruiting	2	120	RoW	RC28-E injection	RemeGen Co., Ltd.	Diabetic Retinopathy	05/24	07/24